Boston Scientific Corporation outlined its long-term growth strategies to a group of investors, demonstrating their product pipeline and planned use of funds to boost its clinical and economic outcomes.

The company announced that it would launch 75 new products by 2022, focusing on providing comprehensive technology and solutions in specific sectors, which would allow it to expand its leadership by $22 billion in high-growth markets in the same time frame.

Boston Scientific also provided goals of completing 80 per cent sales by 2022, and set financial targets of achieving an organic revenue compound annual growth rate increase from 6 per cent to 9 per cent between 2020 and 2022.

Chairman and chief executive officer of Boston Scientific, Mike Mahoney, said: “This is an exciting time for Boston Scientific to help more patients live better and longer lives through the benefits provided by our current medical devices and treatment therapies, while we invest in and develop a robust, long-term pipeline of future technologies.

“We have an outstanding global team that is focused on creating more value for patients, customers and shareholders, and delivering revenue growth faster than our served markets and in the top tier for our sector.”

In particular, the company’s core businesses – MedSurg, Rhythm and Neuro, and Cardiovascular – are expected to expand due to its long-term targets.

Contact us


Tel: +44 (0)1424 777745

Fax: +44 (0)1424 777746



Kirkham Young Ltd.
The Old Court House
North Trade Road
East Sussex
TN33 0EX